Chargement en cours...
4CPS-136 Are cardiovascular adverse events with ibrutinib well considered?
BACKGROUND: Chronic lymphocytic leukaemia and mantle cell lymphoma have a new standard of care: ibrutinib (metabolised by CYP3A4/5 and P-glycoprotein inhibitor). Cardiovascular (CV) adverse events are characterised by atrial fibrillation (AF) (5%–13.8%), bleeding event (BE) (grade 3 or 4 about 3%–4%...
Enregistré dans:
| Publié dans: | Eur J Hosp Pharm |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Group
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535365/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.227 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|